Pharma IQ Members

Antibody Production

Antibody Production, for example, is when animals produce antibodies in response to proteins or other molecules (termed immunogens) recognized as foreign by their immune system. The antibodies are secreted into the plasma by B cells that are able to interact with the immunogen. The intensity of the response is determined by several factors including the size of the immunogen molecule, its chemical characteristics, and how different it is from the animal's own proteins. Most natural immunogens are proteins. The antibody response increases with repeated exposure to the immunogen, so a series of injections at regular intervals is needed to achieve both high levels of antibody production and antibodies of high affinity.

Eric Langer

Key areas driving demand for single-use applications

Single-use applications continue to dominate the list of innovation areas sought by the biopharmaceutical manufacturing community, a testament to the widespread optimism surrounding the...

Contributor: Eric Langer
10/26/2015 08:00:00 PM EDT
Trends and Successes in Disposable Tech

“Changes in lifestyles and healthcare systems, and increasing demand for drugs at reduced prices, has led to the development of facilities that can produce more than one product, offering flexibility and scalability.” (4) Single use systems,...

Contributor: Chanice Henry
09/28/2015 08:00:00 PM EDT
Top 10 Disruptive Technologies in Pharma

When it comes to market innovation, providers tend to split into two camps, the disrupters and the disrupted. Technological advancement is an arena that sees many attempts at sparking revolution. With this in mind, Pharma IQ takes a look at 10 of...

Contributor: Chanice Henry
05/28/2015 08:00:00 PM EDT
Pharma IQ News

Jones Lang LaSalle reports the key considerations for transforming existing facilities to meet the rising demand for biologic medicinesTraditional pharmaceutical manufacturing facilities are being driven into dinosaur status as demand grows for...

Contributor: Pharma IQ News
10/20/2013 08:00:00 PM EDT
Pharma IQ News
Moderate Growth Rate and Increasing Competition for the Therapeutic Proteins Market

The global therapeutic proteins market will grow at a moderate pace, with monoclonal antibodies considered to be the highest revenue generating market in 2010....

Contributor: Pharma IQ News
10/02/2011 08:00:00 PM EDT
Cristina Falcão

What were the odds that the drug makers would roll the dice and have not only a financial mega hit but in Mergers & Acquisitions and Offshore-Production two “star is born “stories in a single show? The whole world is moving to more connected...

Contributor: Cristina Falcão
08/15/2011 08:00:00 PM EDT
Eric Langer

Single use technologies are strong change agents in biopharma manufacturing.  Disposable devices emerge once again as a top new technology of interest among the 352 surveyed biomanufacturers in BioPlan Associates, Inc.’s 2011 8th Annual Report...

Contributor: Eric Langer
08/07/2011 08:00:00 PM EDT
Cost Savings Still the Number One Reason Behind 60% of Outsourced Pharma and Bio Manufacturing

While there is normally more than one factor behind the decision of a pharmaceutical or biopharmaceutical organisation to outsource its global manufacturing, it seems the ever-important cost-saving potential remains among the main attraction of...

Contributor: Pharma IQ
05/16/2011 08:00:00 PM EDT
Eric Langer

During the past six years, single use systems and devices have emerged as a key change agent in the biomanufacturing landscape. Acceptance in R&D and scale-up has been driven by their effectiveness in reducing risks of contamination, faster...

Contributor: Eric Langer
04/05/2011 08:00:00 PM EDT
Pharma IQ

Unwanted immunogenicity can often result in projects being cancelled or severely delayed, to the substantial cost of the developer, and so ensuring this particular process goes smoothly is at the forefront of industry leaders' minds. One...

Contributor: Pharma IQ
02/21/2011 07:00:00 PM EST
Pharma IQ

Antibodies play an essential role in the pharmaceutical industry, particularly in the production of vaccines and antibiotics, and also have the potential to bring in significant revenue. A recently-released La Merie report, entitled Antibody...

Contributor: Pharma IQ
11/10/2010 07:00:00 PM EST
Helen Winsor

Amorphous pharmaceutical materials are now being recognised as an attractive alternative route for solid state development. Dr. Dave Miller, Senior Principal Scientist at Hoffmann-La Roche, speaks to Helen Winsor from Pharma IQ, about the...

Contributor: Helen Winsor
09/05/2010 08:00:00 PM EDT
Helen Winsor

Prof. Nair Rodriguez-Hornedo of the University of Michigan, discusses the latest successful strategies in making co-crystals, providing firsthand examples from the University's Department of Pharmaceutical Sciences. She offers her perspective on...

Contributor: Helen Winsor
07/11/2010 08:00:00 PM EDT
Pharma IQ

Dr. Dave Miller, Senior Principal Scientist at Hoffmann La Roche, shares his views on how to optimise amorphous form selection, techniques to enhance amorphous drug performance and the best strategies to stabilise amorphous forms. He also offers...

Contributor: Pharma IQ
07/11/2010 08:00:00 PM EDT
Be Prepared for Scale Up of Co-crystal Production

Dr. Vaibhav Sihorkar, Head of Pharmaceutical Development at Aurigene Discovery Technologies in India, gave Pharma IQ his insights on existing challenges to co-crystal commercialisation.What is the major challenge in achieving scale up of co-...

Contributor: Vaibhav Sihorkar
07/07/2010 08:00:00 PM EDT
Pharma IQ

Dr Adam O’Neil, Materials Discovery & Characterisation Scientist at Vertex Pharmaceuticals joins Pharma IQ today to discuss best practice techniques to successfully scale up co-crystal production.

Contributor: Pharma IQ
05/26/2010 08:00:00 PM EDT